g star 28
IRVING, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Exela Technologies, Inc. ("Exela” or the "Company”) (NASDAQ: XELA, XELAP), a global business process automation leader, will host a conference call with the financial community to discuss the Company's financial results for the third quarter 2024 at 4:30 p.m. ET on November 29, 2024. Hosting the call and reviewing the results will be Matt Brown, Interim Chief Financial Officer of the Company. The conference call will be broadcast live on Exela's Investor Relations website at https://investors.exelatech.com/ . Third Quarter 2024 Results Webcast and Call Access Information: Shortly after the conclusion of the call, a replay will be available through December 6, 2024 at 877-344-7529 or +1-412-317-0088 (international). The replay passcode is 8557685. To automatically receive Exela financial news by e-mail, please visit the Exela Investor Relations website, http://investors.exelatech.com/ , and subscribe to E-mail Alerts. For more Exela news, commentary, and industry perspectives, visit: Website: https://investors.exelatech.com/ X: @ExelaTech LinkedIn: exela-technologies Facebook: @exelatechnologies Instagram: @exelatechnologies The information posted on the Company's website and/or via its social media accounts may be deemed material to investors. Accordingly, investors, media and others interested in the Company should monitor the Company's website and its social media accounts in addition to the Company's press releases, SEC filings and public conference calls and webcasts. About Exela Exela Technologies is a business process outsourcing and automation leader, leveraging a global footprint and proprietary technology to help turn the complex into the simple through user friendly software platforms and solutions that enable our customers' digital transformation. We have decades of expertise earned from serving more than 4,000 customers worldwide, including many of the world's largest enterprises and over 60% of the Fortune® 100, in many mission-critical environments across multiple industries, including banking, healthcare, insurance and manufacturing. Our technology-enabled solutions allow global organizations to address critical challenges resulting from the massive amounts of data obtained and created through their daily operations. Our solutions address the life cycle of transaction processing and enterprise information management, from enabling payment gateways and data exchanges across multiple systems, to matching inputs against contracts and handling exceptions, to ultimately depositing payments and distributing communications. Through cloud-enabled platforms, built on a configurable stack of automation modules, and approximately 12,600 employees operating in 20 countries, Exela rapidly deploys integrated technology and operations as an end-to-end digital journey partner. Investor and/or Media Contacts: [email protected]Claros Mortgage Trust stock hits 52-week low at $6.07
Older siblings everywhere could appreciate John Harbaugh's refusal to concede an inch against his younger brother Jim. Even when his Baltimore Ravens faced fourth down at their 16-yard line in the second quarter, John wasn't giving up the ball without a fight. The Ravens converted that fourth down and two others on their way to a 30-23 victory over the Los Angeles Chargers on Monday night, giving their coach a third victory in three matchups against his brother. It was the first time they'd faced off since Baltimore beat San Francisco — then coached by Jim Harbaugh — in the Super Bowl at the end of the 2012 season. “We grew up in the same room and have always lived our life side by side, but that’s not what the game is about,” John Harbaugh said. “The game really is about the players, and the players are always going to win the game or lose the game or whatever.” On this night, it was Baltimore's players who shined. Specifically Derrick Henry, who rushed for 140 yards. Lamar Jackson threw a couple of touchdown passes, and the defense was solid, allowing touchdowns on the first and last Los Angeles drives but not much in between. “I’m proud of our guys,” John Harbaugh said. “I’m proud of the way they came out and responded after the first 10 points — we were down 10-0, and our guys stepped up.” After converting fourth-and-1 at their 16 late in the second quarter, the Ravens scored on a 40-yard pass from Jackson to Rashod Bateman, taking the lead for good at 14-10. Baltimore's other two fourth-and-1 conversions came on a 14-play touchdown drive that spanned the end of the third quarter and start of the fourth. “We’re just confident that we’ll end up converting on those fourth downs, and we did a great job blocking,” said Henry, who converted the last two of the fourth downs. "All we had to do was make a play, and we did.” The Ravens got back to their identity a bit, rushing for 212 yards. And it wasn't just Henry and Jackson contributing. Justice Hill broke free for a 51-yard touchdown that made it 30-16 in the fourth. “Nobody wants to stand in front of (Derrick Henry) every single play, every single run,” Hill said. "You can do it one time, two times, three times, but when you have to do it 20 to 25 times, it starts to wear down. I’m glad we stuck with the run game this game, and it played out for us.” There were still too many penalties, with the Ravens flagged nine times for 102 yards. Baltimore played a pretty clean game until the fourth quarter, so several of those flags came after the Ravens had the game reasonably under control, but this is still an area of concern. With star linebacker Roquan Smith out because of a hamstring injury, Malik Harrison led the Ravens with a dozen tackles. “It’s a lot of people that doubted me coming into this game, so I’m happy I was able to ball out and show them that I can be in this league, and I can play at a high level,” Harrison said. There was a time when Isaiah Likely seemed as if he might be supplanting Mark Andrews as Baltimore's top tight end threat, but Likely went without a catch Monday. He did, however, recover the onside kick that effectively ended the game. Although Smith was out, DT Travis Jones (ankle) and C Tyler Linderbaum (back) were able to start. Jackson has now thrown 22 touchdown passes with no interceptions on Monday nights, with a passer rating of 124.3. The Ravens have one more game before their open date, and it's a showdown this weekend against a Philadelphia team that has won seven in a row. Saquon Barkley (1,392) of the Eagles and Henry (1,325) have both surpassed 1,300 yards rushing already. Nobody else in the NFL has more than 1,000. AP NFL: https://apnews.com/hub/nflCharles Schwab Investment Management Inc. raised its position in Innovative Industrial Properties, Inc. ( NYSE:IIPR – Free Report ) by 2.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 457,374 shares of the company’s stock after purchasing an additional 10,711 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Innovative Industrial Properties were worth $61,563,000 as of its most recent SEC filing. A number of other large investors also recently added to or reduced their stakes in the company. USA Financial Formulas purchased a new stake in shares of Innovative Industrial Properties in the 3rd quarter valued at $25,000. Blue Trust Inc. grew its position in Innovative Industrial Properties by 2,085.7% in the 2nd quarter. Blue Trust Inc. now owns 459 shares of the company’s stock valued at $48,000 after acquiring an additional 438 shares in the last quarter. Signaturefd LLC increased its stake in Innovative Industrial Properties by 42.3% during the second quarter. Signaturefd LLC now owns 505 shares of the company’s stock worth $55,000 after purchasing an additional 150 shares during the period. Federated Hermes Inc. lifted its position in shares of Innovative Industrial Properties by 138.1% during the second quarter. Federated Hermes Inc. now owns 538 shares of the company’s stock worth $59,000 after purchasing an additional 312 shares in the last quarter. Finally, US Bancorp DE grew its holdings in shares of Innovative Industrial Properties by 75.3% in the third quarter. US Bancorp DE now owns 440 shares of the company’s stock valued at $59,000 after purchasing an additional 189 shares in the last quarter. 70.58% of the stock is currently owned by institutional investors and hedge funds. Innovative Industrial Properties Price Performance Shares of IIPR opened at $109.17 on Friday. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of 19.43 and a beta of 1.37. The firm’s fifty day simple moving average is $123.47 and its 200-day simple moving average is $118.63. Innovative Industrial Properties, Inc. has a twelve month low of $80.24 and a twelve month high of $138.35. The company has a current ratio of 11.53, a quick ratio of 11.53 and a debt-to-equity ratio of 0.15. Innovative Industrial Properties Dividend Announcement The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, October 15th. Shareholders of record on Monday, September 30th were given a dividend of $1.90 per share. This represents a $7.60 annualized dividend and a yield of 6.96%. The ex-dividend date was Monday, September 30th. Innovative Industrial Properties’s payout ratio is currently 135.23%. Wall Street Analyst Weigh In A number of equities research analysts have issued reports on the stock. Wolfe Research upgraded shares of Innovative Industrial Properties to a “hold” rating in a report on Monday, September 23rd. Compass Point upgraded Innovative Industrial Properties from a “neutral” rating to a “buy” rating and set a $125.00 price objective on the stock in a research note on Friday, November 8th. Piper Sandler lowered their target price on Innovative Industrial Properties from $120.00 to $118.00 and set a “neutral” rating for the company in a research note on Friday, November 8th. Finally, Roth Capital upgraded Innovative Industrial Properties to a “strong-buy” rating in a report on Monday, November 11th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $127.67. View Our Latest Research Report on IIPR Innovative Industrial Properties Company Profile ( Free Report ) Innovative Industrial Properties, Inc is a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized properties leased to experienced, state-licensed operators for their regulated cannabis facilities. Innovative Industrial Properties, Inc has elected to be taxed as a real estate investment trust, commencing with the year ended December 31, 2017. Read More Want to see what other hedge funds are holding IIPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innovative Industrial Properties, Inc. ( NYSE:IIPR – Free Report ). Receive News & Ratings for Innovative Industrial Properties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovative Industrial Properties and related companies with MarketBeat.com's FREE daily email newsletter .
NoneJACKSONVILLE, Fla. (AP) — Keaston Willis scored 15 points off of the bench to help lead Tulsa over Detroit Mercy 63-44 on Tuesday. Willis finished 3 of 9 from 3-point range and 6 for 7 from the line for the Golden Hurricane (4-3). Isaiah Barnes scored 12 points while shooting 4 for 9, including 4 for 6 from beyond the arc and added seven rebounds. Dwon Odom had 11 points and went 5 of 8 from the field. Jared Lary led the way for the Titans (3-4) with 12 points and two steals. Tulsa led 36-27 at halftime, with Willis racking up nine points. Tulsa extended its lead to 54-35 during the second half, fueled by a 9-2 scoring run. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
NoneIND vs AUS 4th Test 2024: Rishabh Pant, Yashasvi Jaiswal Bat out Afternoon Session To Steer India to 112/3 Against AustraliaAmid Political Turbulence, US Lawyers Need to Bolster Respect for the Rule of Law
Trump vows tariffs over immigration. What the numbers say about border crossings, drugs and crime.
A look at how some of Trump's picks to lead health agencies could help carry out Kennedy's overhaul
The team that President-elect Donald Trump has selected to lead federal health agencies in his second administration includes a retired congressman, a surgeon and a former talk-show host. All could play pivotal roles in fulfilling a political agenda that could change how the government goes about safeguarding Americans' health — from health care and medicines to food safety and science research. In line to lead the Department of Health and Human Services secretary is environmental lawyer and anti-vaccine organizer Robert F. Kennedy Jr. Trump's choices don't have experience running large bureaucratic agencies, but they know how to talk about health on TV . Centers for Medicare and Medicaid pick Dr. Mehmet Oz hosted a talk show for 13 years and is a well-known wellness and lifestyle influencer. The pick for the Food and Drug Administration, Dr. Marty Makary, and for surgeon general, Dr. Janette Nesheiwat, are frequent Fox News contributors. Many on the list were critical of COVID-19 measures like masking and booster vaccinations for young people. Some of them have ties to Florida like many of Trump's other Cabinet nominees: Dave Weldon , the pick for the Centers for Disease Control and Prevention, represented the state in Congress for 14 years and is affiliated with a medical group on the state's Atlantic coast. Nesheiwat's brother-in-law is Rep. Mike Waltz , R-Fla., tapped by Trump as national security adviser. Here's a look at the nominees' potential role in carrying out what Kennedy says is the task to “reorganize” agencies, which have an overall $1.7 trillion budget, employ 80,000 scientists, researchers, doctors and other officials, and effect Americans' daily lives: Centers for Disease Control and Prevention The Atlanta-based CDC, with a $9.2 billion core budget, is charged with protecting Americans from disease outbreaks and other public health threats. Kennedy has long attacked vaccines and criticized the CDC, repeatedly alleging corruption at the agency. He said on a 2023 podcast that there is "no vaccine that is safe and effective,” and urged people to resist the CDC's guidelines about if and when kids should get vaccinated . The World Health Organization estimates that vaccines have saved more than 150 million lives over the past 50 years, and that 100 million of them were infants. Decades ago, Kennedy found common ground with Weldon , 71, who served in the Army and worked as an internal medicine doctor before he represented a central Florida congressional district from 1995 to 2009. Starting in the early 2000s, Weldon had a prominent part in a debate about whether there was a relationship between a vaccine preservative called thimerosal and autism. He was a founding member of the Congressional Autism Caucus and tried to ban thimerosal from all vaccines. Kennedy, then a senior attorney for the Natural Resources Defense Council, believed there was a tie between thimerosal and autism and also charged that the government hid documents showing the danger. Since 2001, all vaccines manufactured for the U.S. market and routinely recommended for children 6 years or younger have contained no thimerosal or only trace amounts, with the exception of inactivated influenza vaccine. Meanwhile, study after study after study found no evidence that thimerosal caused autism. Weldon's congressional voting record suggests he may go along with Republican efforts to downsize the CDC, including to eliminate the National Center for Injury Prevention and Control, which works on topics like drownings, drug overdoses and shooting deaths. Weldon also voted to ban federal funding for needle-exchange programs as an approach to reduce overdoses, and the National Rifle Association gave him an “A” rating for his pro-gun rights voting record. Food and Drug Administration Kennedy is extremely critical of the FDA, which has 18,000 employees and is responsible for the safety and effectiveness of prescription drugs, vaccines and other medical products, as well as overseeing cosmetics, electronic cigarettes and most foods. Makary, Trump’s pick to run the FDA, is closely aligned with Kennedy on several topics . The professor at Johns Hopkins University who is a trained surgeon and cancer specialist has decried the overprescribing of drugs, the use of pesticides on foods and the undue influence of pharmaceutical and insurance companies over doctors and government regulators. Kennedy has suggested he'll clear out “entire” FDA departments and also recently threatened to fire FDA employees for “aggressive suppression” of a host of unsubstantiated products and therapies, including stem cells, raw milk , psychedelics and discredited COVID-era treatments like ivermectin and hydroxychloroquine. Makary's contrarian views during the COVID-19 pandemic included questioning the need for masking and giving young kids COVID-19 vaccine boosters. But anything Makary and Kennedy might want to do when it comes to unwinding FDA regulations or revoking long-standing vaccine and drug approvals would be challenging. The agency has lengthy requirements for removing medicines from the market, which are based on federal laws passed by Congress. Centers for Medicaid and Medicare Services The agency provides health care coverage for more than 160 million people through Medicaid, Medicare and the Affordable Care Act, and also sets Medicare payment rates for hospitals, doctors and other providers. With a $1.1 trillion budget and more than 6,000 employees, Oz has a massive agency to run if confirmed — and an agency that Kennedy hasn't talked about much when it comes to his plans. While Trump tried to scrap the Affordable Care Act in his first term, Kennedy has not taken aim at it yet. But he has been critical of Medicaid and Medicare for covering expensive weight-loss drugs — though they're not widely covered by either . Trump said during his campaign that he would protect Medicare, which provides insurance for older Americans. Oz has endorsed expanding Medicare Advantage — a privately run version of Medicare that is popular but also a source of widespread fraud — in an AARP questionnaire during his failed 2022 bid for a U.S. Senate seat in Pennsylvania and in a 2020 Forbes op-ed with a former Kaiser Permanente CEO. Oz also said in a Washington Examiner op-ed with three co-writers that aging healthier and living longer could help fix the U.S. budget deficit because people would work longer and add more to the gross domestic product. Neither Trump nor Kennedy have said much about Medicaid, the insurance program for low-income Americans. Trump's first administration reshaped the program by allowing states to introduce work requirements for recipients. Surgeon general Kennedy doesn't appear to have said much publicly about what he'd like to see from surgeon general position, which is the nation's top doctor and oversees 6,000 U.S. Public Health Service Corps members. The surgeon general has little administrative power, but can be an influential government spokesperson on what counts as a public health danger and what to do about it — suggesting things like warning labels for products and issuing advisories. The current surgeon general, Vivek Murthy, declared gun violence as a public health crisis in June. Trump's pick, Nesheiwat, is employed as a New York City medical director with CityMD, a group of urgent care facilities in the New York and New Jersey area, and has been at City MD for 12 years. She also has appeared on Fox News and other TV shows, authored a book on the “transformative power of prayer” in her medical career and endorses a brand of vitamin supplements. She encouraged COVID-19 vaccines during the pandemic, calling them “a gift from God” in a February 2021 Fox News op-ed, as well as anti-viral pills like Paxlovid. In a 2019 Q&A with the Women in Medicine Legacy Foundation , Nesheiwat said she is a “firm believer in preventive medicine” and “can give a dissertation on hand-washing alone.” National Institutes of Health As of Saturday, Trump had not yet named his choice to lead the National Institutes of Health, which funds medical research through grants to researchers across the nation and conducts its own research. It has a $48 billion budget. Kennedy has said he'd pause drug development and infectious disease research to shift the focus to chronic diseases. He'd like to keep NIH funding from researchers with conflicts of interest, and criticized the agency in 2017 for what he said was not doing enough research into the role of vaccines in autism — an idea that has long been debunked . Associated Press writers Amanda Seitz and Matt Perrone and AP editor Erica Hunzinger contributed to this report. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. This story has been corrected to reflect that the health agencies have an overall budget of about $1.7 trillion, not $1.7 billion. Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. Subscribe to stay connected to Tucson. A subscription helps you access more of the local stories that keep you connected to the community. Build your health & fitness knowledge Sign up here to get the latest health & fitness updates in your inbox every week!